Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.759
Peer-review started: July 25, 2016
First decision: September 2, 2016
Revised: October 23, 2016
Accepted: November 16, 2016
Article in press: November 18, 2016
Published online: December 24, 2016
Processing time: 153 Days and 4.9 Hours
To explore the benefits and harms of corticosteroid (CS) minimization following renal transplantation.
CS minimization attempts to improve cardiovascular risk factors (hypertension, diabetes, dyslipidemia), to enhance growth in children, to ameliorate bone disease and to lead to better compliance with immunosuppressive agents. Nevertheless, any benefit must be carefully weighed against the reduction in net immunosuppression and the potential harm to renal allograft function and survival.
Complete CS avoidance or very early withdrawal (i.e., no CS after post-transplant day 7) seems to be associated with better outcomes in comparison with later withdrawal. However, an increased incidence of CS-sensitive acute rejection has been observed with all CS minimization strategies. Among the prerequisites for the safe application of CS minimization protocols are the administration of induction immunosuppression and the inclusion of calcineurin inhibitors in maintenance immunosuppression regimens.
Transplant recipients at low immunological risk (primary transplant, low panel reactive antibodies) are thought as optimal candidates for CS minimization. CS avoidance may also be undesirable in patients at risk for glomerulonephritis recurrence or with severe delayed graft function and prolonged cold ischemia time. Thus, CS minimization is not yet ready for implementation in the majority of transplant recipients.
Core tip: Although corticosteroids have been traditional components of immunosuppressive regimens in renal transplantation, corticosteroid minimization strategies are developed in an attempt to mitigate their many side-effects. The benefit from this approach must be balanced against the risk of acute rejection due to insufficient immunosuppression and the potential harm to allograft survival. We present an overview of these strategies and their impact on clinical outcomes analyzing the key clinical trials performed. Furthermore, we focus on patient selection according to the immunological risk and the induction immunosuppression, the principal factors that determine the success of corticosteroid withdrawal and avoidance protocols.